BACKGROUND: Daily suppressive therapy with valacyclovir reduces risk of sexual transmission of herpes simplex virus type 2 (HSV-2) in HSV-2-serodiscordant heterosexual couples by 48%. Whether suppressive therapy reduces HSV-2 transmission from persons coinfected with HSV-2 and human immunodeficiency virus type 1 (HIV-1) is unknown. METHODS: Within a randomized trial of daily acyclovir 400 mg twice daily in African HIV-1 serodiscordant couples, in which the HIV-1-infected partner was HSV-2 seropositive, we identified partnerships in which HIV-1-susceptible partners were HSV-2 seronegative to estimate the effect of acyclovir on risk of HSV-2 transmission. RESULTS: We randomly assigned 911 HSV-2/HIV-1-serodiscordant couples to daily receipt of acyclovir or placebo. We observed 68 HSV-2 seroconversions, 40 and 28 in acyclovir and placebo groups, respectively (HSV-2 incidence, 5.1 cases per 100 person-years; hazard ratio [HR], 1.35 [95% confidence interval, .83-2.20]; P = .22). Among HSV-2-susceptible women, vaginal drying practices (adjusted HR, 44.35; P = .004) and unprotected sex (adjusted HR, 9.91; P = .002) were significant risk factors for HSV-2 acquisition; having more children was protective (adjusted HR, 0.47 per additional child; P = .012). Among HSV-2-susceptible men, only age ≤30 years was associated with increased risk of HSV-2 acquisition (P = .016). CONCLUSIONS: Treatment of African HSV-2/HIV-1-infected persons with daily suppressive acyclovir did not decrease risk of HSV-2 transmission to susceptible partners. More-effective prevention strategies to reduce HSV-2 transmission from HIV-1-infected persons are needed.
BACKGROUND: Daily suppressive therapy with valacyclovir reduces risk of sexual transmission of herpes simplex virus type 2 (HSV-2) in HSV-2-serodiscordant heterosexual couples by 48%. Whether suppressive therapy reduces HSV-2 transmission from persons coinfected with HSV-2 and human immunodeficiency virus type 1 (HIV-1) is unknown. METHODS: Within a randomized trial of daily acyclovir 400 mg twice daily in African HIV-1 serodiscordant couples, in which the HIV-1-infected partner was HSV-2 seropositive, we identified partnerships in which HIV-1-susceptible partners were HSV-2 seronegative to estimate the effect of acyclovir on risk of HSV-2 transmission. RESULTS: We randomly assigned 911 HSV-2/HIV-1-serodiscordant couples to daily receipt of acyclovir or placebo. We observed 68 HSV-2 seroconversions, 40 and 28 in acyclovir and placebo groups, respectively (HSV-2 incidence, 5.1 cases per 100 person-years; hazard ratio [HR], 1.35 [95% confidence interval, .83-2.20]; P = .22). Among HSV-2-susceptible women, vaginal drying practices (adjusted HR, 44.35; P = .004) and unprotected sex (adjusted HR, 9.91; P = .002) were significant risk factors for HSV-2 acquisition; having more children was protective (adjusted HR, 0.47 per additional child; P = .012). Among HSV-2-susceptible men, only age ≤30 years was associated with increased risk of HSV-2 acquisition (P = .016). CONCLUSIONS: Treatment of African HSV-2/HIV-1-infected persons with daily suppressive acyclovir did not decrease risk of HSV-2 transmission to susceptible partners. More-effective prevention strategies to reduce HSV-2 transmission from HIV-1-infected persons are needed.
Authors: Philippe Van de Perre; Michel Segondy; Vincent Foulongne; Abdoulaye Ouedraogo; Issouf Konate; Jean-Marie Huraux; Philippe Mayaud; Nicolas Nagot Journal: Lancet Infect Dis Date: 2008-08 Impact factor: 25.071
Authors: Jairam R Lingappa; Jared M Baeten; Anna Wald; James P Hughes; Katherine K Thomas; Andrew Mujugira; Nelly Mugo; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; James Kiarie; Carey Farquhar; Grace John Stewart; Joseph Makhema; Myron Essex; Edwin Were; Kenneth H Fife; Guy de Bruyn; Glenda E Gray; James A McIntyre; Rachel Manongi; Saidi Kapiga; David Coetzee; Susan Allen; Mubiana Inambao; Kayitesi Kayitenkore; Etienne Karita; William Kanweka; Sinead Delany; Helen Rees; Bellington Vwalika; Amalia S Magaret; Richard S Wang; Lara Kidoguchi; Linda Barnes; Renee Ridzon; Lawrence Corey; Connie Celum Journal: Lancet Date: 2010-02-12 Impact factor: 79.321
Authors: C Celum; A Wald; J R Lingappa; A S Magaret; R S Wang; N Mugo; A Mujugira; J M Baeten; J I Mullins; J P Hughes; E A Bukusi; C R Cohen; E Katabira; A Ronald; J Kiarie; C Farquhar; G J Stewart; J Makhema; M Essex; E Were; K H Fife; G de Bruyn; G E Gray; J A McIntyre; R Manongi; S Kapiga; D Coetzee; S Allen; M Inambao; K Kayitenkore; E Karita; W Kanweka; S Delany; H Rees; B Vwalika; W Stevens; M S Campbell; K K Thomas; R W Coombs; R Morrow; W L H Whittington; M J McElrath; L Barnes; R Ridzon; L Corey Journal: N Engl J Med Date: 2010-01-20 Impact factor: 91.245
Authors: Thomas L Cherpes; Leslie A Meyn; Marijane A Krohn; Joel G Lurie; Sharon L Hillier Journal: Clin Infect Dis Date: 2003-07-15 Impact factor: 9.079
Authors: Aaron A R Tobian; Blake Charvat; Victor Ssempijja; Godfrey Kigozi; David Serwadda; Frederick Makumbi; Boaz Iga; Oliver Laeyendecker; Melissa Riedesel; Amy Oliver; Michael Z Chen; Steven J Reynolds; Maria J Wawer; Ronald H Gray; Thomas C Quinn Journal: J Infect Dis Date: 2009-04-01 Impact factor: 5.226
Authors: M Augenbraun; J Feldman; K Chirgwin; J Zenilman; L Clarke; J DeHovitz; S Landesman; H Minkoff Journal: Ann Intern Med Date: 1995-12-01 Impact factor: 25.391
Authors: Hatem A Elshabrawy; Jilao Fan; Christine S Haddad; Kiira Ratia; Christopher C Broder; Michael Caffrey; Bellur S Prabhakar Journal: J Virol Date: 2014-02-05 Impact factor: 5.103
Authors: Mary K Grabowski; Godfrey Kigozi; Ronald H Gray; Benjamin Armour; Jordyn Manucci; David Serwadda; Andrew D Redd; Fred Nalugoda; Eshan U Patel; Maria J Wawer; Thomas C Quinn; Aaron A R Tobian Journal: J Infect Dis Date: 2015-05-05 Impact factor: 5.226
Authors: Emily S Ford; Amalia S Magaret; Cedric W Spak; Stacy Selke; Steve Kuntz; Lawrence Corey; Anna Wald Journal: AIDS Date: 2018-11-13 Impact factor: 4.177
Authors: Kenneth H Fife; Kenneth Mugwanya; Katherine K Thomas; Jared M Baeten; Connie Celum; Elizabeth Bukusi; Guy de Bruyn; Andrew Mujugira; Bellington Vwalika; Anna Wald; Jairam R Lingappa Journal: J Infect Dis Date: 2015-12-23 Impact factor: 5.226
Authors: Amalia S Magaret; Andrew Mujugira; James P Hughes; Jairam Lingappa; Elizabeth A Bukusi; Guy DeBruyn; Sinead Delany-Moretlwe; Kenneth H Fife; Glenda E Gray; Saidi Kapiga; Etienne Karita; Nelly R Mugo; Helen Rees; Allan Ronald; Bellington Vwalika; Edwin Were; Connie Celum; Anna Wald Journal: Clin Infect Dis Date: 2015-11-17 Impact factor: 9.079
Authors: Paula A Suazo; Francisco J Ibañez; Angello R Retamal-Díaz; Marysol V Paz-Fiblas; Susan M Bueno; Alexis M Kalergis; Pablo A González Journal: Mediators Inflamm Date: 2015-03-30 Impact factor: 4.711